Recombinant Canine CD40, Fc tagged

• Cat.No.: CD40-167C
• Product Overview: Recombinant Canine CD40 (Q7YRL5) (Met1-Ala194), fused with the Fc region of human IgG1 at the C-terminus, was produced in Human Cells.

Specification

• Source: Human Cells
• Species: Canine
• Tag: Fc
• Predicted N Terminal: Glu 21
• Form: Lyophilized from sterile PBS, pH 7.4.Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization.
• Molecular Mass: The recombinant canine CD40/Fc is a disulfide-linked homodimer. The reduced monomer comprises 415 amino acids and has a predicted molecular mass of 46.1 kDa. The apparent molecular mass of the protein is approximately 50-56 kDa in SDS-PAGE under reducing
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >95 % as determined by SDS-PAGE
• Stability: Samples are stable for up to twelve months from date of receipt at -70oC.
• Storage: Store it under sterile conditions at -20oC~-70oC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4℃ before opening to recover the entire contents.
• Protein length: Met1-Ala194

Gene Information

• Gene Name: CD40?CD40 molecule, TNF receptor superfamily member 5 [?Canis lupus familiaris?(dog) ]
• Official Symbol: CD40
• Gene ID: 403469
• mRNA Refseq: NM_001002982
• Protein Refseq: NP_001002982
• UniProt ID: Q7YRL5
• Chromosome Location: 24

Reviews

10/28/2021

Its utilization in this technique has allowed for precise visualization and determination of protein structures with remarkable clarity and resolution.

08/11/2021

The reliable and high-quality results obtained using CD40 protein make it an excellent choice for researchers studying protein structures.

10/07/2018

CD40 protein has proved to be an invaluable tool in protein electron microscopy structure analysis.

Q&As

Can CD40-targeted therapies be used in the treatment of infectious diseases?

CD40 agonists have the potential to enhance immune responses against infectious agents, but their clinical use in this context is an area of ongoing research.

Are there any approved drugs targeting CD40 for clinical use?

As of my knowledge cutoff date in January 2022, there were no FDA-approved drugs specifically targeting CD40. However, clinical trials were ongoing for CD40-targeted therapies.

Can CD40-targeted therapies be used in combination with other cancer treatments?

Yes, CD40-targeted therapies are often investigated in combination with other treatments like checkpoint inhibitors or chemotherapy to enhance their effectiveness.

What are the potential side effects of CD40-targeted therapies in cancer treatment?

Side effects may include flu-like symptoms, cytokine release syndrome, and immune-related adverse events, which can be managed with supportive care and close monitoring.

Are there ongoing clinical trials exploring CD40-targeted therapies for atherosclerosis?

Research on CD40-targeted therapies for atherosclerosis is still in the experimental stages and not yet in advanced clinical trials.